Participants were enrolled down to an estimated glomerular filtration rate (eGFR) of 20 mL/min/1.73m2, and there is no evidence that the beneficial effects of SGLT-2 inhibition on kidney disease progression or cardiovascular risk are attenuated across the spectrum of eGFR studied [4]. The gene discussed is SLC5A2; the disease is kidney disorder.